Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial

Fig. 4

Rates of PRO improvements ≥ MCID (a) or ≥ normative values (b) at week 16 (overall population). *Statistically significant difference. MCID values: HAQ-DI ≥ − 0.35, SF-36 PCS ≥ 2.5, SF-36 MCS ≥ 2.5, FACIT-F ≥ − 4.0 and SF-36 domains ≥5.0. Normative values: HAQ-DI ≥ 0.5, SF-36 PCS ≥ 50, SF-36 MCS ≥ 50 and FACIT-F ≥ 40.1. CI confidence interval, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue scale, HAQ-DI Health Assessment Questionnaire-Disability Index, MCID minimal clinically important difference, MCS mental component summary, PCS physical component summary, PRO patient-reported outcome, SF-36 Short Form-36

Back to article page